Allied Market Research
Loading...
0
New
New
2021
Oncology/cancer Drugs Market

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2027

A00042
Pages: 242
Mar 2021 | 136316 Views
   
Author(s) : Sayali Shinde, Smita Nerkar , Onkar Sumant
Tables: 99
Charts: 70
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Oncology/cancer Drugs Market

Request Now !

Oncology Drugs Market Overview:

The global oncology drugs market was valued at $128,352 million in 2019, and is projected to reach $222,380 million by 2027, registering a CAGR of 7.4%.

Cancer is a group of diseases associated with abnormal cell growth with the potential to plague or spread to other parts of the body. Major types of cancers include carcinomas, sarcomas, lymphomas, and leukemia. Sarcomas begin in the connective tissue such as muscle or bones. Soft-tissue sarcomas can begin in fatty tissues. Moreover, the treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and others. Furthermore, biological drugs on the basis of monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.

Oncology-Cancer-Drugs-market

Get more information on this report : Request Sample Pages

The COVID-19 pandemic has disrupted virtually each aspect of healthcare provision including cancer care. The outbreak of Coronavirus disease (COVID-19) has acted as a significant restraint on the oncology/cancer drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. In addition, COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. COVID-19 pandemic has impacted the most crucial areas of the oncology/cancer drugs market by disrupting clinical trials and drug supply chains. Pandemic has directly affected the supply of oncology drugs to cancer patients; it is difficult to administer chemotherapy and certain other treatments outside of a clinic. Also, the spread of coronavirus has reduced patients’ willingness and ability to access not just treatments, but trials for new medicines. COVID-19’s interference with the research and development of new treatments is one of the most significant blows to the cancer drugs market. According to, Centre for Drug Development (UK), the pandemic initially drew recruitment for UK clinical trials to an almost complete pause. 

The growth of the global oncology/cancer drugs market is majorly driven by increase in incidence of various cancer conditions, rise in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth. However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

Oncology/Cancer Drugs Market
By Drug Class Type

Your browser does not support the canvas element.

Targeted Therapy is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

The global oncology/cancer drugs market is segmented on the basis of drug class type, indication, and region. By drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Segmental review

By drug class type, the targeted therapy segment is anticipated to grow with the largest share throughout the forecast period. This is attributed to the identification of molecular targets of cancer cells. Recent advances in cellular technology and gene therapy have contributed to improve the understanding of tumor cells and their metabolism at molecular level, thus driving the need for targeted drug therapies for cancer treatment. On the other side, the demand for immunotherapy is projected to exhibit the fastest global oncology/cancer drugs market. growth during the forecast period. 

Oncology/Cancer Drugs Market
By Indication

Your browser does not support the canvas element.

Breast Cancer holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

North America accounted for the largest share of revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027, owing to presence of large patient population and early adoption of advance drugs. However, Asia-Pacific is expected to grow at the highest CAGR, owing to increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers. Moreover, rise in incidence of cancer worldwide fuels the global oncology/cancer drugs market growth.

Some of the key players operating in the global oncology/cancer drugs market. include AbbVie Inc. Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc.

Oncology/Cancer Drugs Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 9.4% during 2020-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global oncology/cancer drugs market trends from 2020 to 2027 to identify the prevailing opportunities along with the strategic assessment. global oncology/cancer drugs market.
  • The oncology/cancer drugs market forecast is studied from 2020 to 2027.
  • The oncology/cancer drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the oncology/cancer drugs market.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the oncology/cancer drugs market.

Key Market Segments

By Drug Class Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies, 2019

3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Clinical trials
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidence of cancer across the globe
3.6.1.2.Surge in global geriatric population
3.6.1.3.Increase in government expenditure on healthcare

3.6.2.Restraints

3.6.2.1.Adverse effects associated with the use cancer drugs

3.6.3.Opportunities

3.6.3.1.High growth potential in untapped emerging economies
3.6.3.2.Increase in number of pipeline drugs

3.6.4.Impact analysis

3.7.COVID-19 impact analysis on oncology/ cancer drugs market

CHAPTER 4:ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Chemotherapy

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Targeted therapy

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Immunotherapy (biologic therapy)

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Hormonal therapy

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:ONCOLOGY/ONCOLOGY/CANCER DRUGS MARKET, BY INDICATIION

5.1.Overview

5.1.1.Market size and forecast

5.2.Lung cancer

5.2.1.Market size and forecast, by region
5.2.2.Market share analysis, by country

5.3.Stomach cancer

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Colorectal cancer

5.4.1.Market size and forecast, by region
5.4.2.Market share analysis, by country

5.5.Breast cancer

5.5.1.Market size and forecast, by region
5.5.2.Market share analysis, by country

5.6.Prostate cancer

5.6.1.Market size and forecast, by region
5.6.2.Market share analysis, by country

5.7.Liver cancer

5.7.1.Market size and forecast, by region
5.7.2.Market share analysis, by country

5.8.Esophagus cancer

5.8.1.Market size and forecast, by region
5.8.2.Market share analysis, by country

5.9.Cervical cancer

5.9.1.Market size and forecast, by region
5.9.2.Market share analysis, by country

5.10.Kidney cancer

5.10.1.Market size and forecast, by region
5.10.2.Market share analysis, by country

5.11.Bladder cancer

5.11.1.Market size and forecast, by region
5.11.2.Market share analysis, by country

5.12.Other cancers

5.12.1.Market size and forecast, by region
5.12.2.Market share analysis, by country

CHAPTER 6:ONCOLOGY/CANCER DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country

6.2.2.1.U.S.

6.2.2.1.1.U.S. Oncology/Cancer Drugs Market, by drug class type
6.2.2.1.2.U.S. oncology/Cancer Drugs Market, by indication

6.2.2.2.Canada

6.2.2.2.1.Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2.Canada oncology/cancer drugs market, by indication

6.2.2.3.Mexico

6.2.2.3.1.Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2.Mexico Oncology/Cancer Drugs Market, by indication

6.2.3.Market size and forecast, by drug class type
6.2.4.Market size and forecast, by indication

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country

6.3.2.1.Germany

6.3.2.1.1.Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2.Germany oncology/cancer drugs market, by indication

6.3.2.2.France

6.3.2.2.1.France oncology/cancer drugs market, by drug class type
6.3.2.2.2.France oncology/cancer drugs market, by indication

6.3.2.3.UK

6.3.2.3.1.UK oncology/cancer drugs market, by drug class type
6.3.2.3.2.UK oncology/cancer drugs market, by indication

6.3.2.4.Italy

6.3.2.4.1.Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2.Italy oncology/cancer drugs market, by indication

6.3.2.5.Spain

6.3.2.5.1.Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2.Spain oncology/cancer drugs market, by indication

6.3.2.6.Rest of Europe

6.3.2.6.1.Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2.Rest of Europe oncology/cancer drugs market, by indication

6.3.3.Market size and forecast, by drug class type
6.3.4.Market size and forecast, by indication

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country

6.4.2.1.Japan

6.4.2.1.1.Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2.Japan oncology/cancer drugs market, by indication

6.4.2.2.China

6.4.2.2.1.China oncology/cancer drugs market, by drug class type
6.4.2.2.2.China oncology/cancer drugs market, by indication

6.4.2.3.Australia

6.4.2.3.1.Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2.Australia oncology/cancer drugs market, by indication

6.4.2.4.India

6.4.2.4.1.India cancer oncology/cancer market, by drug class type
6.4.2.4.2.India oncology/cancer drugs market, by indication

6.4.2.5.South Korea

6.4.2.5.1.South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2.South Korea oncology/cancer drugs market, by indication

6.4.2.6.Rest of Asia-Pacific

6.4.2.6.1.Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2.Rest of Asia-Pacific oncology/cancer drugs market, by indication

6.4.3.Market size and forecast, by drug class type
6.4.4.Market size and forecast, by indication

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country

6.5.2.1.Brazil

6.5.2.1.1.Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2.Brazil oncology/cancer drugs market, by indication

6.5.2.2.Saudi Arabia

6.5.2.2.1.Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2.Saudi Arabia oncology/cancer drugs market, by indication

6.5.2.3.South Africa

6.5.2.3.1.South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2.South Africa oncology/cancer drugs market, by indication

6.5.2.4.Rest of LAMEA

6.5.2.4.1.Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2.Rest of LAMEA cancer drugs market, by indication

6.5.3.Market size and forecast, by drug class type
6.5.4.Market size and forecast, by indication

CHAPTER 7:COMPANY PROFILES

7.1.ABBVIE INC.

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments

7.2.AMGEN INC.

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.ASTELLAS PHARMA INC.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product Portfolio
7.3.5.Business performance

7.4.ASTRAZENECA PLC.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product Portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments

7.5.BRISTOL-MYERS SQUIBB COMPANY

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product Portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.F. HOFFMANN-LA ROCHE LTD.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.6.6.Key strategic moves and developments

7.7.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.MERCK & CO., INC.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product Portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.NOVARTIS INTERNATIONAL AG (SANDOZ)

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PFIZER INC.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance

LIST OF TABLES

TABLE 01.COMPLETED CLINICAL TRIALS IN CANCER DRUGS MARKET, 2017–2021
TABLE 02.ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 03.ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 04.ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 05.ONCOLOGY/CANCER DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY REGION, 2019–2027 ($MILLION)
TABLE 06.ONCOLOGY/CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027($MILLION)
TABLE 08.ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2019–2027($MILLION)
TABLE 09.ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2019–2027($MILLION)
TABLE 10.ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2027($MILLION)
TABLE 11.ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2019–2027($MILLION)
TABLE 12.ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027($MILLION)
TABLE 13.ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2019–2027($MILLION)
TABLE 14.ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 2019–2027($MILLION)
TABLE 15.ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2019–2027($MILLION)
TABLE 16.ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2019–2027($MILLION)
TABLE 17.ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2019–2027($MILLION)
TABLE 18.ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 2019–2027 ($MILLION)
TABLE 19.ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 22.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 23.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 24.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 25.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 26.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 27.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 28.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 33.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 34.UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 35.UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 36.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 37.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 38.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 39.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 40.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 41.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 42.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 43.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 45.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 46.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 47.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 48.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 49.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 50.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 51.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 52.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 53.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 54.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 55.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 56.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 57.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 61.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 62.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 63.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 64.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 65.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 66.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 67.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 68.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 69.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.ABBVIE: COMPANY SNAPSHOT
TABLE 71.ABBVIE: OPERATING SEGMENT
TABLE 72.ABBVIE: PRODUCT PORTFOLIO
TABLE 73.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74.AMGEN: COMPANY SNAPSHOT
TABLE 75.AMGEN: OPERATING SEGMENT
TABLE 76.AMGEN: PRODUCT PORTFOLIO
TABLE 77.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78.ASTELLAS: COMPANY SNAPSHOT
TABLE 79.ASTELLAS: PRODUCT PORTFOLIO
TABLE 80.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 81.ASTRAZENECA: OPERATING SEGMENTS
TABLE 82.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 83.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 84.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 85.ROCHE: COMPANY SNAPSHOT
TABLE 86.ROCHE: OPERATING SEGMENTS
TABLE 87.ROCHE: PRODUCT PORTFOLIO
TABLE 88.J&J: COMPANY SNAPSHOT
TABLE 89.J&J: OPERATING SEGMENTS
TABLE 90.J&J: PRODUCT TYPE PORTFOLIO
TABLE 91.MERCK: COMPANY SNAPSHOT
TABLE 92.MERCK: OPERATING SEGMENTS
TABLE 93.MERCK: PRODUCT PORTFOLIO
TABLE 94.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 95.NOVARTIS: OPERATING SEGMENTS
TABLE 96.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 97.PFIZER: COMPANY SNAPSHOT
TABLE 98.PFIZER: OPERATING SEGMENTS
TABLE 99.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2019
FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2017–2019
FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2019
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGANING POWER OF BUYERS
FIGURE 08.HIGH BARGANING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.HIGH COMPETITIVE RIVALRY
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR CHEMOTHERAPY BY COUNTRY,  2019–2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR TARGETED THERAPY BY COUNTRY, 2019–2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR IMMUNOTHERAPY (BIOLOGIC THERAPY) BY COUNTRY, 2019–2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET, FOR HORMONAL THERAPY BY COUNTRY, 2019–2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY,  2019 & 2027
FIGURE 18.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2019 & 2027
FIGURE 19.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2019 & 2027
FIGURE 20.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY,  2019 & 2027
FIGURE 21.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY,  2019 & 2027
FIGURE 22.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2019 & 2027
FIGURE 23.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2019 & 2027
FIGURE 24.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2019 & 2027
FIGURE 25.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2019 & 2027
FIGURE 26.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2019 & 2027
FIGURE 27.COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2019 & 2027
FIGURE 28.U.S. ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 29.CANADA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 30.MEXICO ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 33.UK ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 34.ITALY ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 35.SPAIN ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 36.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 37.JAPAN ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 38.CHINA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 39.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 40.INDIA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 41.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 42.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 43.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 44.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 45.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 46.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 47.ABBVIE: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.ABBVIE: REVENUE SHARE BY REGION, 2019(%)
FIGURE 49.AMGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.AMGEN: REVENUE SHARE BY REGION, 2019(%)
FIGURE 51.ASTELLAS: SALES, 2017–2019 ($MILLION)
FIGURE 52.ASTRAZENECA: REVENUE, 2018–2020 ($MILLION)
FIGURE 53.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 54.REVENUE, 2018–2020 ($MILLION)
FIGURE 55.BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 56.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 58.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 59.J&J: REVENUE, 2018–2020 ($MILLION)
FIGURE 60.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 61.J&J: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 62.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 63.MERCK: NET SALES BY SEGMENT, 2019 (%)
FIGURE 64.MERCK: NET SALES BY REGION, 2019 (%)
FIGURE 65.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 66.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 67.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 68.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 69.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 70.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

 
 

In accordance to several interviews conducted, the utilization of cancer drugs is expected to witness a significant rise is increase in prevalence of cancer in both developed and developing economies. Furthermore, the global oncology/cancer drugs market growth is propelled by surge in geriatric population, increase in collaboration between pharmaceutical companies for development of novel cancer drugs, and rise in awareness associated with early detection of cancer among populace. 

North America accounted for the highest market share in 2019, due to availability of advance cancer drugs, higher cancer awareness, and heavy expenditure by the government on healthcare, followed by Europe and Asia-Pacific. Asia Pacific is expected to exhibit fastest market growth due to increase in incidence of cancer. Pharmaceutical companies have focused on expanding their presence in emerging economies, which is anticipated to drive the market growth.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Cancer is a group of diseases associated with abnormal cell growth with the potential to plague or spread to other parts of the body. Major types of cancers include carcinomas, sarcomas, lymphomas, and leukemia.

A. Treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and others.

A. Drug class type segment is the most influencing segment owing increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market

A. The total market value of Oncology Cancer Drugs Market is $2,22,380.0 million in 2019.

A. Top companies such as,AbbVie Inc. Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in rigions.

A. The base year is 2019 in Oncology Cancer Drugs Market

A. The forcast period for Oncology Cancer Drugs Market is 2020 to 2027

A. The market value of Oncology Cancer Drugs Market in 2020 is $1,34,884.8 million.

A. North America accounted for the largest share of revenue in 2019, and is anticipated to maintain its dominance from 2020 to 2027, owing to presence of large patient population and early adoption of advance drugs. However, Asia-Pacific is expected to grow at the highest CAGR, owing to increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers.

A. The major factor that fuels the growth of the Oncology Cancer Drugs Market includes driven by increase in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Oncology/cancer Drugs Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers